Indication
Lennox-Gastaut syndrome treatment adjunct
Lennox-Gastaut syndrome is a severe developmental and epileptic encephalopathy primarily presenting in early childhood and persisting throughout life. Read more about Lennox-Gastaut syndrome treatment adjunct
34 drugs 27 manufacturers
Drugs that treat it
Common Lennox-Gastaut syndrome treatment adjunct therapies.
ONFI (clobazam)
CLOBAZAM
CLOBAZAM
CLOBAZAM
CLOBAZAM
CLOBAZAM
CLOBAZAM
CLOBAZAM
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonLennox-Gastaut syndrome is a severe developmental and epileptic encephalopathy primarily presenting in early childhood and persisting throughout life.
The central nervous system condition is clinically characterized by a classic triad of drug-resistant, polymorphic seizures—predominantly tonic, atonic drop, and atypical absence seizures—alongside progressive cognitive impairment and distinct electroencephalographic features, notably interictal slow spike-and-wave discharges and paroxysmal fast activity during sleep.
Because the underlying seizure burden is profoundly refractory to single-agent regimens, adjunctive treatment involves using add-on therapies in combination with baseline antiseizure medications to optimize seizure reduction and mitigate associated morbidity.
- nih.gov
Lennox-Gastaut syndrome is a severe developmental and epileptic encephalopathy primarily presenting in early childhood and persisting throughout life The central nervous system condition is clinically characterized by a classic triad of drug-resistant, polymorphic seizures—predominantly tonic, atonic drop, and atypical absence seizures—alongside progressive cognitive impairment and distinct electroencephalographic features, notably interictal slow spike-and-wave discharges and paroxysmal fast ac...
- nih.gov
Lennox-Gastaut syndrome is a severe developmental and epileptic encephalopathy primarily presenting in early childhood and persisting throughout life Because the underlying seizure burden is profoundly refractory to single-agent regimens, adjunctive treatment involves using add-on therapies in combination with baseline antiseizure medications to optimize seizure reduction and mitigate associated morbidity
- nih.gov
The central nervous system condition is clinically characterized by a classic triad of drug-resistant, polymorphic seizures—predominantly tonic, atonic drop, and atypical absence seizures—alongside progressive cognitive impairment and distinct electroencephalographic features, notably interictal slow spike-and-wave discharges and paroxysmal fast activity during sleep
- utah.edu
The central nervous system condition is clinically characterized by a classic triad of drug-resistant, polymorphic seizures—predominantly tonic, atonic drop, and atypical absence seizures—alongside progressive cognitive impairment and distinct electroencephalographic features, notably interictal slow spike-and-wave discharges and paroxysmal fast activity during sleep
- nih.gov
Because the underlying seizure burden is profoundly refractory to single-agent regimens, adjunctive treatment involves using add-on therapies in combination with baseline antiseizure medications to optimize seizure reduction and mitigate associated morbidity
Personalize your experience
Follow Lennox-Gastaut syndrome treatment adjunct and get updates as they land.
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.